Constellation Pharmaceuticals was a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. MorphoSys acquired Constellation in 2021 and then Novartis acquired MorphoSys in 2024. Novartis continues to develop pelabresib in patients with myelofibrosis.
Constellation Pharmaceuticals
TAP Partner
Cambridge, Massachusetts
United States
Project Title
Program
Therapy Acceleration Program